1-20 of 41
Leif W. Ellisen
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Abstract 7472: Metabolic mechanisms underlying late recurrence in hormone receptor positive breast cancer

Free
Bryce Ordway, Isabella Vianna, Johannes Kreuzer, Wilhelm Haas, Dennis Sgroi, Leif W. Ellisen
Journal: Cancer Research
Cancer Res (2025) 85 (8_Supplement_1): 7472.
https://doi.org/10.1158/1538-7445.AM2025-7472
Published: 21 April 2025
View articletitled, Abstract 7472: Metabolic mechanisms underlying late recurrence in hormone receptor positive breast cancer
Journal Articles

Abstract 6582: HD-PTP modulates anti-tumor immunity via extracellular vesicles in triple-negative breast cancer

Free
Chenxu Guo, Sheng Sun, Nayana Thimmiah, Ilze Smidt, Shufeng Zhou, Thomas J. Kania, Taisha Joseph, Mark N. Melkonyan, Siang B. Koh, Leif W. Ellisen
Journal: Cancer Research
Cancer Res (2025) 85 (8_Supplement_1): 6582.
https://doi.org/10.1158/1538-7445.AM2025-6582
Published: 21 April 2025
View articletitled, Abstract 6582: HD-PTP modulates anti-tumor immunity via extracellular vesicles in triple-negative breast cancer
Journal Articles

Abstract 4449: SIRT5 promotes chemoresistance through metabolic rewiring for nucleotide replenishing in refractory triple negative breast cancer

Free
Zuen Ren, Kiran Kurmi, Tiziano Bernasocchi, Eric Zaniewski, Shakchhi Joshi, Garrett Lam, Chenxu (Vincent) Guo, Ilze Smidt, Preshita Dave, Agustina Maccio, Johannes Kreuzer, Gabrielle Elena Gioia, Veerle I. Bossuyt, Brian N. Dontchos, Gary X. Wang, Shinn-Huey S. Chou, Michael Lawrence, Esther Rheinbay, Laura M. Spring, Wilhelm Haas, Raul Mostoslavsky, Marcia C. Haigis, Leif W. Ellisen
Journal: Cancer Research
Cancer Res (2025) 85 (8_Supplement_1): 4449.
https://doi.org/10.1158/1538-7445.AM2025-4449
Published: 21 April 2025
View articletitled, Abstract 4449: SIRT5 promotes chemoresistance through metabolic rewiring for nucleotide replenishing in refractory triple negative breast cancer
Journal Articles

Abstract 1521: Chromatin remodeler ACTL6A in CD8+ T cells promotes antitumor immunity

Free
Bogang Wu, Win Thant, Elena Bitman, Ting Liu, Leif W. Ellisen
Journal: Cancer Research
Cancer Res (2024) 84 (6_Supplement): 1521.
https://doi.org/10.1158/1538-7445.AM2024-1521
Published: 22 March 2024
View articletitled, Abstract 1521: Chromatin remodeler ACTL6A in CD8+ T cells promotes antitumor immunity
Journal Articles

Abstract 5858: Systematic identification of pathways associated with antibody drug conjugate sensitivity in breast cancer

Free
Bogang Wu, Sheng Sun, Nayana Thimmiah, Aiko Nagayama, James T. Coates, Ting Liu, Win Thant, Elena Bitman, David Li, John Doench, Aditya Bardia, Leif W. Ellisen
Journal: Cancer Research
Cancer Res (2024) 84 (6_Supplement): 5858.
https://doi.org/10.1158/1538-7445.AM2024-5858
Published: 22 March 2024
View articletitled, Abstract 5858: Systematic identification of pathways associated with antibody drug conjugate sensitivity in breast cancer
Journal Articles

Abstract 5850: Multiomics analysis unravels tumor metabolic reprogramming and potential resistance mechanism(s) to curative therapy in TNBC

Free
Zuen Ren, Kiran Kurmi, Robert Morris, Shakchhi Joshi, Eric Zaniewski, Johannes Kreuzer, Gabrielle Elena Gioia, Veerle I. Bossuyt, Brian N. Dontchos, Gary X. Wang, Shinn-Huey S. Chou, Laura M. Spring, Wilhelm Haas, Marcia C. Haigis, Leif W. Ellisen
Journal: Cancer Research
Cancer Res (2024) 84 (6_Supplement): 5850.
https://doi.org/10.1158/1538-7445.AM2024-5850
Published: 22 March 2024
View articletitled, Abstract 5850: Multiomics analysis unravels tumor metabolic reprogramming and potential resistance mechanism(s) to curative therapy in TNBC
Journal Articles

Abstract PR08: Intratumoral heterogeneity drives resistance to Antibody Drug Conjugate therapy: Analysis of the NeoSTAR trial of neoadjuvant Sacituzumab govitecan for localized TNBC

Free
Laura M. Spring, Bogang Wu, Ting Liu, Jacob Geisberg, Simona Cristea, Veerle Bossuyt, Rachel Occhiogrosso Abelman, Nicole Peiris, James Coates, Siang-Boon Koh, Mengran Zhang, Lianne Ryan, Beverly Moy, Steven J. Isakoff, Sara M. Tolaney, Franziska Michor, Aditya Bardia, Leif W. Ellisen
Journal: Cancer Research
Cancer Res (2024) 84 (3_Supplement_1): PR08.
https://doi.org/10.1158/1538-7445.ADVBC23-PR08
Published: 01 February 2024
View articletitled, Abstract PR08: Intratumoral heterogeneity drives resistance to Antibody Drug Conjugate therapy: Analysis of the NeoSTAR trial of neoadjuvant Sacituzumab govitecan for localized TNBC
Journal Articles

Abstract 3680: Multiomics analysis of triple negative breast cancer identifies potential metabolic vulnerability for overcoming the resistance of neoadjuvant therapy

Free
Zuen Ren, Kiran Kurmi, Robert Morris, Shakchhi Joshi, Eric Zaniewski, Johannes Kreuzer, Gabrielle Elena Gioia, Wilhelm Haas, Marcia C. Haigis, Leif W. Ellisen
Journal: Cancer Research
Cancer Res (2023) 83 (7_Supplement): 3680.
https://doi.org/10.1158/1538-7445.AM2023-3680
Published: 04 April 2023
View articletitled, Abstract 3680: Multiomics analysis of triple negative breast cancer identifies potential metabolic vulnerability for overcoming the resistance of neoadjuvant therapy
Journal Articles

Abstract 767: Genomics and transcriptomics profiling of BRCA mutation carriers revealed the landscape of early pathogenesis of BRCA1/2-associated breast cancer

Free
Zuen Ren, Po-Han Lin, Siang Boon Koh, Kai Stewart, Nick Haradhvala, Aylin S Dedeoglu, Ilze Smidt, Akiko Suzuki, David Li, Win Thant, Sarah Mueller, Taisha Joseph, Veerle Bossuyt, Michael Lawrence, Gad Getz, Leif W. Ellisen
Journal: Cancer Research
Cancer Res (2023) 83 (7_Supplement): 767.
https://doi.org/10.1158/1538-7445.AM2023-767
Published: 04 April 2023
View articletitled, Abstract 767: Genomics and transcriptomics profiling of BRCA mutation carriers revealed the landscape of early pathogenesis of BRCA1/2-associated breast cancer
Journal Articles

Abstract 960: Overlapping expression landscape of antibody drug conjugate targets, trophoblast cell surface antigen 2 (Trop-2) & human epidermal growth factor receptor 2 (HER2), in breast cancer

Free
Arielle J. Medford, Nicholas J. Haradhvala, Neelima Vidula, Rachel Abelman, Laura M. Spring, Leif W. Ellisen, Gad Getz, Aditya Bardia
Journal: Cancer Research
Cancer Res (2023) 83 (7_Supplement): 960.
https://doi.org/10.1158/1538-7445.AM2023-960
Published: 04 April 2023
View articletitled, Abstract 960: Overlapping expression landscape of antibody drug conjugate targets, trophoblast cell surface antigen 2 (Trop-2) & human epidermal growth factor receptor 2 (HER2), in breast cancer
Journal Articles

Abstract 5248: CDK4/6 inhibition (CDK4/6i) is effective in the real-world setting for hormone receptor-positive metastatic breast cancer (HR+ MBC) with ESR1 mutations and fusions

Free
Jamie O. Brett, Caroline M. Weipert, Lauren L. Ritterhouse, Nicole Zhang, Junhua Yu, Lianne Y. Ryan, Laura M. Spring, Miguel N. Rivera, Jochen K. Lennerz, Dora Dias-Santagata, Leif W. Ellisen, Aditya Bardia, Seth A. Wander
Journal: Cancer Research
Cancer Res (2022) 82 (12_Supplement): 5248.
https://doi.org/10.1158/1538-7445.AM2022-5248
Published: 15 June 2022
View articletitled, Abstract 5248: CDK4/6 inhibition (CDK4/6i) is effective in the real-world setting for hormone receptor-positive metastatic breast cancer (HR+ MBC) with ESR1 mutations and fusions
Journal Articles

Abstract P5-13-21: Relationship between circulating tumor DNA and response to neoadjuvant niraparib in HER2-negative, BRCA-mutated breast cancer

Free
Ming Shan, Laura Spring, Minetta C Liu, Erika Hamilton, Hanna Irie, Cesar A Santa-Maria, Steven J Isakoff, James Reeves, Leif W Ellisen, Lee P Lim, Kavita Garg, Caterina Bertucci, Bin Feng, Hailei Zhang, Kaiming Sun, Julie R Graham, Erin Hofstatter, Hyo Han
Journal: Cancer Research
Cancer Res (2022) 82 (4_Supplement): P5-13-21.
https://doi.org/10.1158/1538-7445.SABCS21-P5-13-21
Published: 15 February 2022
View articletitled, Abstract P5-13-21: Relationship between circulating tumor DNA and response to neoadjuvant niraparib in HER2-negative, BRCA-mutated breast cancer
Journal Articles

Abstract P3-09-11: Clinical characteristics associated withBRCA1/2mutations identified on routine tumor tissue genotyping in metastatic breast cancer

Free
Neelima Vidula, Erica Blouch, Alexander Farahani, Hetal Marble, Andrzej Niemierko, Kathleen Hesler, Elyssa Denault, Dejan Juric, Leif W. Ellisen, Beverly Moy, Steven Isakoff, Jochen Lennerz, Aditya Bardia
Journal: Cancer Research
Cancer Res (2022) 82 (4_Supplement): P3-09-11.
https://doi.org/10.1158/1538-7445.SABCS21-P3-09-11
Published: 15 February 2022
View articletitled, Abstract P3-09-11: Clinical characteristics associated withBRCA1/2mutations identified on routine tumor tissue genotyping in metastatic breast cancer
Journal Articles

Abstract OT2-24-03: Phase II study of a PARP inhibitor in metastatic breast cancer with somaticBRCA1/2mutations identified by cell-free DNA: Genotyping based clinical trial

Free
Neelima Vidula, Erica Blouch, Erin Basile, Nathan Royce Ruffle-Deignan, Nora Horick, Senthil Damodaran, Alvaro Moreno Aspitia, Manali Bhave, Ami Shah, Minetta C. Liu, Joseph Sparano, Harry Ostrer, Hope Rugo, Leif W. Ellisen, Aditya Bardia
Journal: Cancer Research
Cancer Res (2022) 82 (4_Supplement): OT2-24-03.
https://doi.org/10.1158/1538-7445.SABCS21-OT2-24-03
Published: 15 February 2022
View articletitled, Abstract OT2-24-03: Phase II study of a PARP inhibitor in metastatic breast cancer with somaticBRCA1/2mutations identified by cell-free DNA: Genotyping based clinical trial
Journal Articles

Abstract P1-18-22: AKT inhibition in combination with endocrine therapy and a CDK4/6 inhibitor (CDK4/6i) in patients with hormone receptor positive (HR+)/HER2 negative metastatic breast cancer (MBC) and prior CDK4/6i exposure: A translational investigation

Free
Seth A. Wander, Douglas S. Micalizzi, Taronish Dubash, Dejan Juric, Laura M. Spring, Neelima Vidula, Jennifer Keenan, Maureen Beeler, Elene Viscosi, Dante Che, Elizabeth L. Fisher, Rachel A. Hepp, Beverly Moy, Steven J. Isakoff, Leif W. Ellisen, Jeffrey G. Supko, Shyamala Maheswaran, Daniel A. Haber, Aditya Bardia
Journal: Cancer Research
Cancer Res (2022) 82 (4_Supplement): P1-18-22.
https://doi.org/10.1158/1538-7445.SABCS21-P1-18-22
Published: 15 February 2022
View articletitled, Abstract P1-18-22: AKT inhibition in combination with endocrine therapy and a CDK4/6 inhibitor (CDK4/6i) in patients with hormone receptor positive (HR+)/HER2 negative metastatic breast cancer (MBC) and prior CDK4/6i exposure: A translational investigation
Journal Articles

Abstract P3-23-02: Immunogenicity of SARS-CoV-2 vaccines in patients with breast cancer receiving CDK 4/6 inhibitors

Free
Elyssa Denault, Erika Nakajima, Vivek Naranbhai, Alejandro Balazs, Lindsey Mortensen, Elizabeth Niehoff, Caroline Barabell, Jennifer A. Hutchinson, Seth A. Wander, Aron S. Rosenstock, Leif W. Ellisen, Beverly Moy, Steven J. Isakoff, Justin F. Gainor, A. John Iafrate, Aditya Bardia, Laura M. Spring
Journal: Cancer Research
Cancer Res (2022) 82 (4_Supplement): P3-23-02.
https://doi.org/10.1158/1538-7445.SABCS21-P3-23-02
Published: 15 February 2022
View articletitled, Abstract P3-23-02: Immunogenicity of SARS-CoV-2 vaccines in patients with breast cancer receiving CDK 4/6 inhibitors
Journal Articles

Abstract PS18-19: Comparison of metastatic genomic profile in patients ≤45 years and patients >45 years with triple-negative breast cancer

Free
Neelima Vidula, Andrzej Niemierko, Katherine Hesler, Steven Isakoff, Dejan Juric, Jennifer Shin, Laura Spring, Jeffrey Peppercorn, Jerry Younger, Irene Kuter, Beverly Moy, Leif W. Ellisen, Aditya Bardia
Journal: Cancer Research
Cancer Res (2021) 81 (4_Supplement): PS18-19.
https://doi.org/10.1158/1538-7445.SABCS20-PS18-19
Published: 15 February 2021
View articletitled, Abstract PS18-19: Comparison of metastatic genomic profile in patients ≤45 years and patients >45 years with triple-negative breast cancer
Journal Articles

Abstract PS17-02: Molecular alterations in the androgen receptor and associated clinical outcomes in hormone receptor-positive/HER2- metastatic breast cancer

Free
Charles Dai, Andrzej Niemierko, Neelima Vidula, Laura M Spring, Seth A Wander, Arielle J Medford, Katherine A Hesler, Giuliana Malvarosa, Jeffrey Peppercorn, Dejan Juric, Steven J Isakoff, Beverly Moy, Leif W Ellisen, Aditya Bardia
Journal: Cancer Research
Cancer Res (2021) 81 (4_Supplement): PS17-02.
https://doi.org/10.1158/1538-7445.SABCS20-PS17-02
Published: 15 February 2021
View articletitled, Abstract PS17-02: Molecular alterations in the androgen receptor and associated clinical outcomes in hormone receptor-positive/HER2- metastatic breast cancer
Journal Articles

Abstract OT-30-02: Phase II study of talazoparib, a PARP inhibitor, in somatic BRCA1/2 mutant metastatic breast cancer

Free
Neelima Vidula, Nora Horick, Erin Basile, Erica Blouch, Leif W. Ellisen, Hope S. Rugo, Aditya Bardia
Journal: Cancer Research
Cancer Res (2021) 81 (4_Supplement): OT-30-02.
https://doi.org/10.1158/1538-7445.SABCS20-OT-30-02
Published: 15 February 2021
View articletitled, Abstract OT-30-02: Phase II study of talazoparib, a PARP inhibitor, in somatic BRCA1/2 mutant metastatic breast cancer
Journal Articles

Abstract OT-03-06: Phase 2 study of response-guided neoadjuvant sacituzumab govitecan (IMMU-132) in patients with localized triple-negative breast cancer (NeoSTAR)

Free
Laura M. Spring, Sara M. Tolaney, Neelam Desai, Amy Comander, Therese Mulvey, Ian E. Krop, Eric P. Winer, Elizabeth A. Mittendorf, Leif W. Ellisen, Aditya Bardia
Journal: Cancer Research
Cancer Res (2021) 81 (4_Supplement): OT-03-06.
https://doi.org/10.1158/1538-7445.SABCS20-OT-03-06
Published: 15 February 2021
View articletitled, Abstract OT-03-06: Phase 2 study of response-guided neoadjuvant sacituzumab govitecan (IMMU-132) in patients with localized triple-negative breast cancer (NeoSTAR)